S-1/A: Sagimet Biosciences Files Amendment for Series A Common Stock Offering

Sagimet Biosciences has filed an amendment to its S-1 registration statement for a proposed offering of 9,000,000 shares of Series A common stock.

Summary

• Sagimet Biosciences has filed an amendment to its Form S-1 registration statement.
• The company is proposing to offer 9,000,000 shares of its Series A common stock to the public.
• An additional 1,350,000 shares may be offered by the underwriters through an option to purchase.
• The Series A common stock is listed on the Nasdaq Global Market under the symbol SGMT.
• The last reported sale price of the Series A common stock on January 22, 2024, was $18.42 per share.
• Sagimet is an emerging growth company and a smaller reporting company, which allows it to comply with certain reduced reporting requirements.
• The company has two series of common stock, Series A and Series B, with identical rights except for voting and conversion.
• Each share of Series A common stock is entitled to one vote, while Series B common stock is non-voting, but convertible into Series A common stock.
• As of December 31, 2023, Sagimet had approximately $94.9 million in cash, cash equivalents, and short-term investments.
• The company intends to use approximately $130.0 million to advance the development of denifanstat and begin startup activities related to the pivotal Phase 3 program in NASH, including manufacturing of additional drug supply.
• Approximately $8.0 million will be used to advance the development of TVB-3567 and submit an IND for a Phase 1 clinical trial for the treatment of acne.
• The remainder will be used for other general corporate purposes, including additional clinical development, working capital, and operating expenses.

Sentiment

Score: 6

Explanation: The document contains both positive and negative elements. The positive topline results from the FASCINATE-2 Phase 2b clinical trial are encouraging, but the company's history of losses and need for additional funding present risks. The sentiment is neutral, reflecting the inherent uncertainties in biopharmaceutical development.

Positives

• The company has identified specific uses for the net proceeds from the offering.
• The company has a clinical-stage biopharmaceutical pipeline.

Negatives

• The company has incurred significant operating losses since its inception and expects to continue to do so.
• The company will require substantial additional capital to finance its operations.
• The company's business depends on the success of its lead drug candidate, denifanstat, which is still in clinical development.

Risks

• The company may never become profitable or be able to sustain profitability.
• The company may be forced to delay, reduce, or eliminate one or more of its research and drug development programs or future commercialization efforts if it is unable to raise capital.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome.
• The company may not be successful in its efforts to expand its pipeline.
• Interim, top-line, and preliminary data from clinical trials may change as more patient data become available.
• The company has licensed rights to denifanstat to Ascletis, a significant stockholder, for Greater China, and Ascletis controls certain product development efforts in its territory, including conduct of clinical trials, which could have an impact on the company's clinical development programs.
• The company may attempt to seek approval from the FDA or comparable foreign regulatory authorities through the use of the accelerated approval pathway, and if it is unable to obtain such approval, it may be required to conduct additional clinical trials beyond those that it contemplates, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals.
• The company may engage in strategic transactions that could increase its capital requirements, dilute its stockholders, cause it to incur debt or assume contingent liabilities, subject it to other risks, adversely affect its liquidity, increase its expenses and present significant distractions to its management.
• If the company is unable to obtain, maintain, and enforce sufficient patent protection for its drug candidates, or if the scope of the patent protection is not sufficiently broad, third parties, including its competitors, could develop and commercialize products similar or identical to its, and its ability to commercialize its drug candidates successfully may be adversely affected.
• The company relies on third parties to conduct its clinical trials of its drug candidates and expects to rely on third parties to conduct future clinical trials, as well as investigator-sponsored clinical trials of its drug candidates, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, the company may not be able to obtain regulatory approval for or commercialize its drug candidates and its business could be substantially harmed.
• The company has relied on, and it expects to continue to rely on, third-party manufacturers to produce its drug candidates, and its manufacturers may experience manufacturing difficulties due to the ongoing effects of inflationary pressures, resource constraints, labor disputes or unstable political environments, which could delay the completion of its clinical trials, increase the costs associated with maintaining clinical trial programs and, significantly impact its ability to develop, obtain regulatory approval for, or market denifanstat and any future drug candidates.
• The company's quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause its stock price to fluctuate or decline.
• The company's principal stockholders and management own a significant percentage of its common stock and have the ability to exercise significant control over matters subject to stockholder approval.
• Unfavorable global political or economic conditions could adversely affect the company's business, financial condition or results of operations.

Future Outlook

The company believes that the net proceeds from this offering, together with its existing cash, cash equivalents and short-term investments in marketable securities, will be sufficient to fund its operations through the first quarter of 2026.

Industry Context

The document highlights the competitive landscape in the NASH treatment space, with numerous companies developing therapies. Sagimet emphasizes the differentiated mechanism of action of denifanstat and its potential as a backbone therapy for combination treatments.

Comparison to Industry Standards

• The document mentions several companies developing treatments for NASH, including 89bio, Akero Therapeutics, Altimmune, Bristol-Myers Squibb, Eli Lilly, Galmed Pharmaceuticals, Gilead Sciences, Intercept Pharmaceuticals, Inventiva, Madrigal Pharmaceuticals, NGM Biopharmaceuticals, NorthSea Therapeutics, Novartis, Novo Nordisk, Pfizer, Terns Pharmaceuticals, Viking Therapeutics, and Zydus Therapeutics.
• The document compares denifanstat's mechanism of action to other approaches, such as enzyme-specific inhibitors, gene expression activators, growth factor analogs, and anti-inflammation/anti-fibrotics.
• The document references the BELOB study for recurrent GBM as a historical benchmark for bevacizumab monotherapy.

Management Changes

Related Party Transactions

• The company has a license agreement with Ascletis BioScience Co. Ltd., a subsidiary of Ascletis Pharma Inc., a significant stockholder.
• The company has entered into an Assignment and Assumption Agreement with Ascletis and Ascletis affiliate Gannex under which Ascletis, while remaining responsible for performance under the license agreement, assigned all of its rights and obligations under the license agreement to Gannex and Gannex assumed such rights and obligations, effective as of October 2019.

Stakeholder Impact

• The offering will dilute existing stockholders.
• The company's success is dependent on the performance of its employees and management team.
• The company's ability to develop and commercialize its drug candidates will impact patients with NASH, acne, and certain forms of cancer.

Next Steps

• The company is currently designing a pivotal Phase 3 program for denifanstat in NASH.
• The company expects to file an IND with the FDA in the first half of 2024 to conduct a first-in-human Phase 1 clinical trial of TVB-3567 for the treatment of acne.

Key Dates

Keywords

Series A common stock, denifanstat, NASH, FASN inhibitor, clinical trials, offering, biopharmaceutical, Ascletis, TVB-3567, acne